Skip to main content

In this file photo taken on June 13, 2017, health workers work at an Ebola quarantine unit on June 13, 2017 in Muma, Congo.

JOHN WESSELS/Getty Images

The World Health Organization said on Friday it hopes to deploy an experimental Ebola vaccine to tackle an outbreak in a remote area of Congo to prevent it spreading, particularly to the provincial capital of 1 million people.

Congo reported the outbreak on Tuesday, with 32 suspected, probable or confirmed cases of the disease since April 4, including 18 deaths. A new suspected case was reported on Friday.

The WHO is moving quickly, having been criticized for bungling its response to a 2014-2016 outbreak that killed more than 11,300 people in Guinea, Sierra Leone and Liberia.

Story continues below advertisement

“We are very concerned and planning for all scenarios, including the worst case scenario,” Peter Salama, WHO’s Deputy Director-General of Emergency Preparedness and Response, told a regular U.N. briefing in Geneva.

The outbreak area is 15 hours by motorbike from the closest town and has “absolutely dire” infrastructure, Salama said, so the WHO wants to send in 20-40 experts by helicopter this weekend and then clear an airstrip for more supplies.

“This is going to be tough and it’s going to be costly to stamp out this outbreak,” he said.

The immediate risk was to the provincial capital Mbandaka, with about 1 million inhabitants, but Congo’s nine neighbors have also been put on high alert in case the disease crossed a border, especially by river to the Republic of Congo or Central African Republic.

Normally a remote setting would reduce the chance of the disease spreading. But already there are three separate locations covering 60 km (37 miles) or more, and some of the victims were healthcare workers, potentially “an amplification factor” for outbreaks, Salama said.

The local culture, with traditional healers and communal burials where there was close contact with the deceased, could cause “super-spreading” of Ebola, which kills up to 90 percent of sufferers, he said.

SUB-ZERO

Story continues below advertisement

Salama said he spoke to Congo’s Health Minister Oly Ilunga on Thursday and hoped to get approval within days to use a vaccine developed by Merck in 2016.

Although highly effective, it is still experimental, has not been licensed, and must be kept at -60 to -80 degrees Celsius (-76°F to -112°F).

“This is a highly complicated, sophisticated operation in one of the most difficult terrains on earth,” Salama said.

It can be used to protect people who have had contact with Ebola victims, stopping the spread of disease, but that requires intensive contact tracing, which Salama said could take a week or two just for the cases already documented.

Ilunga said on Thursday that the risk to urban areas and cases among healthcare workers made the outbreak worrisome, and that health workers might be the priority for vaccination.

Salama said that WHO was preparing for the green light and hoped to have a mobile laboratory operational over the weekend, and that both WHO and the medical charity Medecins Sans Frontieres already had a team on the ground.

Story continues below advertisement

“The cold chain is on standby, the stockpile is on standby, the teams have been put on standby including up to 40 people that conducted the initial ring vaccination trial in Guinea.”

Salama also said there was no evidence of a link between the outbreak and eight deaths that occurred in January and February in the same area, which had not been confirmed as Ebola.

Stephen Douglas, a journalist reporting on Ebola in Sierra Leone shares his story of visiting King Tom Cemetery in Freetown Globe and Mail Update
Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.